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Abstract 
 
Post-transcriptional regulation by microRNA (miRNA) is an important aspect of 
androgen receptor (AR) signalling in prostate cancer cells. However, the global 
profiling of miRNA expression in prostate cancer cells following treatment with AR 
ligands has not been reported so far. In this study we examined the effect of treatment 
with two AR agonists (mibolerone (MIB) and dihydrotestosterone (DHT)) and an AR 
antagonist (bicalutamide (BIC)) on miRNA expression in the human androgen-
dependent LNCaP prostate cancer cell line using microarray technology and 
verification of selected miRNA using quantitative real-time PCR (qRT-PCR). No 
miRNA were identified as differentially expressed following treatment with the AR 
antagonist BIC. In contrast, a number of common and compound-specific alterations 
in miRNA expression were observed following treatment with AR agonists. 
Unexpectedly it was found that treatment with the AR agonists resulted in the 
repression of miR-221, a miRNA previously established to be involved with prostate 
cancer development. This observation indicates that this miRNA may have a more 
complex role in prostate cancer development than considered previously. Treatment 
with MIB led to an induction of miR-210 expression, a hypoxia-related miRNA. This 
miRNA is reported to be involved in cell adaptation to hypoxia and thus induction in 
conditions of normoxia may be important in driving metabolic changes observed in 
prostate cancer. Thus examining the effect of AR agonists and antagonists on miRNA 
expression can provide novel insights into the response of cells to AR ligands and 
subsequent downstream events. 
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Introduction 
 
The androgen receptor (AR) is a member of the steroid hormone receptor family that 
is expressed in various types of tissues. Activation of AR intracellular signalling 
pathways by natural androgens such as testosterone and dihydroxytestosterone (DHT) 
is necessary for the development and maintenance of male characteristics in 
vertebrates (Heinlein & Chang, 2002). The prostate in particular is an organ that 
requires the action of androgens on the AR in order to develop and function. The 
dependency of prostate cells on androgen-mediated AR signalling for development 
and maintenance is also retained in the majority of prostate tumours (Heinlein 
& Chang, 2004). AR antagonists inhibit the effect of AR, acting by a variety of 
mechanisms such as competitive binding to the AR and the blocking of androgen 
synthesis. Given the dependency of prostate cancer cells on AR signalling for growth 
and survival, AR inhibitors are valuable clinical tools for the treatment of prostate 
cancer patients (Heinlein & Chang, 2004). 
 
It is being increasingly recognized that post-transcriptional regulation by non-coding 
miRNA is an important mechanism by which the activated AR modulates the 
phenotype of prostate cells. In the setting of prostate cancer AR regulated miRNA 
have been reported to be associated with the development and severity of the disease.  
Examples include the miR-99/let-7c/miR-125b miRNA cluster involved in the 
regulation of multiple androgen-induced genes (Sun et al., 2014), the epigenetically 
repressed miR-31 which is a direct regulator of the AR (Lin et al., 2013), and miR-
221 which has been linked to the progression of prostate cancer cells to a state of 
androgen independence (Sun et al. 2009; Sun et al., 2014). Studies aiming to 
investigate the role of miRNA in AR signalling and prostate cancer have taken a 
variety of approaches. These include the identification of miRNA that target the AR 
receptor (Östling et al., 2011), comparison of androgen sensitive and insensitive cell 
lines (Ottman et al., 2014), comparison of miRNA expression between metastatic and 
non-metastatic prostate cancer cell lines (Saini et al., 2011), and examination of 
miRNA expression in prostate tumour samples (Szczyrba et al., 2010).  
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In this study we used a different approach, investigating the effect of direct treatment 
with two AR agonists and one AR inhibitor on the expression of miRNA in LNCaP 
cells, an androgen-dependent prostate cancer cell line, using miRNA microarray 
followed by verification of individual differentially expressed miRNAs using qRT-
PCR. This approach has a number of advantages. Firstly, it allows the direct 
comparison of the effect of treatment with AR agonists and antagonists on the 
miRNA expression of prostate cancer cell lines. Secondly, it can be used to determine 
compound-specific effects on miRNA expression. Lastly, it allows the identification 
of novel AR-regulated miRNA and miRNA implicated in the AR regulatory network. 
We have used DHT, the most potent endogenous androgenic compound (Luu-The V 
et al., 2008) and mibolerone (MIB), a potent non-metabolisable synthetic androgen 
agonist, originally used by veterinarians to prevent oestrus in female dogs 
(Sokolowski and Geng, 1977).  MIB has been used extensively in cell culture assays 
to study effects of the AR.  Additionally we have examined bicalutamide (BIC), also 
known as Casodex®, a therapeutic non-steroidal androgen antagonist used as part of a 
regimen in the treatment of androgen-sensitive prostate cancer (Fradet, 2004).  
 
Materials & Methods 
 
Cell culture 
 
All cell culture reagents were supplied by Life Technologies (Paisley, UK) unless 
otherwise stated, and cells were propagated in Corning® standard tissue culture 
plastic-ware. Human LNCaP cells were purchased from ATCC at passage number 17 
and experiments were conducted within 10 passages of the original number. LNCaP 
were routinely cultured in complete media consisting of phenol red-free minimum 
essential medium supplemented with 10% v/v foetal bovine serum (FBS), 1% v/v 
non-essential amino acids, 2mM L-glutamine, and 1% Penicillin/Streptomycin 
(100U/mL, 100μg/mL respectively). 
 
Cell treatments  
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BIC and DHT were purchased from Sigma-Aldrich (Gillingham, UK). MIB was 
obtained from Perkin Elmer (Waltham, MA, USA). Prior to administration of the 
treatments LNCaP cells were plated at 50,000 cells/mL in steroid-depleted (stripped) 
media for 2 days, to reduce the amount of endogenous steroids and growth factors, 
thus potentially lowering the total testosterone by as much as 80% (Sedelaar and 
Isaacs, 2009).  The actions of exogenous steroids can then be assessed without 
influence from endogenous steroids. The dextran-coated charcoal stripped FBS 
(dccFBS) was generated as described previously (Papaioannou et al., 2014) and added 
to the experimental media at a concentration of 5%.   
 
Cell Proliferation 
 
Cell numbers were assessed using a haemocytometer and viability assessed using 
trypan blue exclusion or using AlamarBlue® assay (AbD Serotec, 2009). 
AlamarBlue® indicator dye changes colour and fluoresces in response to the chemical 
reduction of resazurin to fluorescent resorufin by metabolically competent cells (AbD 
Serotec, 2009); the amount of reduction is directly proportional to the number of cells 
present in the sample.  Samples were examined at various times after treatment. 
 
Enzyme-linked immunosorbent assay (ELISA) assays 
     
PSA expression was measured using PSA enzyme-linked immunosorbent assay 
(ELISA) kit PS067T as per the manufacturer‟s protocol (Calbiotech, Spring Valley, 
CA, USA). The amount of PSA was determined by comparison to the standard curve 
which was run concurrently with each set of samples.  The cellular supernatant 
containing the secreted PSA, diluted with distilled water as required, was used to 
assess PSA secretion. Samples were examined at various times after treatment. 
   
EGF expression was measured using Human EGF ELISA kit KHG0061 as per the 
manufacturer‟s recommendations (Life Technologies).  EGF expression was 
determined by comparison to a standard curve.   
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Hypoxia culturing conditions 
Based on previous reports (Giannakakis et al., 2008) 16 hours of 1% O2 was used to 
induce hypoxia in LNCaP. Cells were grown to approximately 70% confluence, the 
media was refreshed (normal culturing media) and flasks transferred to 1% O2 
(hypoxia) or maintained in control conditions (21% O2 normoxia). After 16 hours, the 
normoxic and hypoxic cultures were harvested for RNA and protein extraction. 
 
RNA extraction 
 
To prevent RNA degradation by RNAses, all reagents were certified RNase-free and 
RNaseZap® (Life Technologies) was used to decontaminate surfaces and pipettes. 
Isolation of RNA from cells was performed using TRIzol® (Life Technologies) 
following the manufacturer‟s instructions. RNA pellets were re-suspended in 40µL of 
Tris/EDTA (TE) buffer pH 8.0 and assessed for concentration and quality. All RNA 
samples used for subsequent work had 260/280 ratios greater than 2.0 and 260/230 
ratios greater than 1.8.  Additionally, an RNA integrity number (RIN) was generated 
for each sample using the RNA Nano reagents and an Agilent Bioanalyser (Agilent 
Technologies, Santa Clara, CA, USA).  All samples used for subsequent work had 
RIN greater than 7.6.  
 
miRNA microarrays 
 
Profiling of global miRNA expression in LNCaP was performed using the Agilent 
Human miRNA Microarray kit (V3) and microarray platform as described previously 
(Koufaris et al., 2012). On each microarray 851 human miRNAs were present, 
consisting of 680 dominant miRNA and 171 *miRNA.   
 
Microarray pre-processing and normalisation 
 
Processing and normalisation of the microarray data were conducted in the R 
statistical programming language (R version 13.2; http://www.r-project.org), using the 
“AgiMicroRna” software package, version 2.2, available as part of the BioConductor 
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Project (http://www.bioconductor.org). miRNAs were retained in the analysis if they 
were declared present in at least 75% of samples within at least one experimental 
condition (treatment and time) and above the threshold (negative control expression 
level plus 1.5x standard deviation) in at least 25% of samples within at least one 
experimental condition. The microarray data were normalised using the robust multi-
array average method with quantile normalisation. ComBat was used to reduce batch 
effects (Johnson et al., 2007).  
 
Microarray analysis 
 
For data collected over multiple time points, time course analysis was conducted in 
AgiMicroRna using Limma with the method of Benjamini-Hochberg used to control 
the false discovery rate to 30% 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
 
qRT-PCR was used to verify differentially expressed miRNAs identified by 
microarray, For mature miRNA qRT-PCR reactions, pre-designed Taqman probes 
were used (Applied Biosystems). The PCR reactions were performed in an ABI Prism 
7700 Sequence Detection System. All PCR reactions were run in triplicate to provide 
technical replicates.  Relative quantification was performed using the 2
-ΔΔCT
 method 
and using RNU6B as the reference gene. In addition to the no-RT, a „no-template 
control‟ (no-TC) was also run to ensure the reagents were free of contaminants.  
 
The Applied Biosystems High Capacity cDNA reverse transcription kit with RNase 
inhibitor (Part number 4374966) with the VEGF TaqMan® Gene Expression Assay 
(Hs00900055_m1) or TaqMan Ribosomal RNA Control Reagents was employed to 
measure VEGF and 18S levels, respectively.   
 
 
Results 
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Effects of DHT, MIB, and BIC treatments on proliferation and PSA secretion in 
LNCaP cells 
 
Two established end-points and surrogate markers of AR activation in prostate cells 
are increased proliferation and PSA secretion. We initially examined the effects of 
DHT, MIB, and BIC on proliferation (Suppl.Fig.1A-C) and PSA secretion 
(Suppl.Fig.2A-C) in LNCaP cells. In addition, the ability of a range of BIC doses to 
inhibit DHT-induced proliferation (Suppl.Fig.1D) and PSA secretion (Suppl.Fig.2D) 
were also examined. As expected DHT and MIB treatments induced dose-dependent 
increases in LNCaP proliferation and PSA secretion. Whilst BIC  treatment alone induced a 
modest increase in proliferation and PSA secretion, in the presence of DHT it had its reported antagonistic effect.  
The modest induction by BIC may be due to a mismatch between the availability of co-regulators and the amount 
required for full antagonism (Hodgson et al, 2007). 
 
Based on these results a single concentration of each compound was selected for 
subsequent study (BIC 10µM – therapeutically relevant concentration, DHT 2nM – 
physiologically relevant concentration, MIB 100pM – induction of maximal 
proliferative response). The effects of these doses were examined at multiple time 
points after treatment initiation (4, 8, 24 and 120 hours) in order to determine 
temporal changes in cell number, PSA secretion, and miRNA expression. The number 
of LNCaP cells at each treatment time point was first determined (Fig.1A). BIC 
treatment resulted in a similar trend as the vehicle control, namely a slight increase in 
cell number over the study period, although at 120 hours of BIC treatment there was a 
statistically significant decrease in cell number (18% reduction compared to vehicle 
control; p<0.05). In the case of DHT a time-dependent increase in cell number was 
observed, reaching a statistically significant increase above the time-matched control 
at 120 hours (122% increase compared to vehicle control; p<0.01). Treatment with 
MIB elicited an even more prominent increase in cell number, reaching statistical 
significance at 120 hours (190% compared to vehicle, p<0.001).  
 
In conjunction with the assessment of cell numbers, PSA secretion was assayed at 
each time point (Fig.1B). In BIC and vehicle treated cells a trend for a steady increase 
in PSA over time was observed. As expected the two AR agonists caused prominent 
increases in PSA secretion. There was a 7.3-fold increase and 10.3-fold increase in 
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 9 
DHT-treated cells compared with the control at 24 hours and 120 hours, respectively. 
Similarly, by 24 hours, MIB had induced an 8-fold increase in PSA and, by 120 
hours, PSA was 36.2 times higher than observed in the time-matched control.    
 
Microarray profiling of miRNA expression 
 
Having characterised the phenotypic response of LNCaP cells to the AR ligands 
(Fig.1; Suppl.Fig.1-2), we examined the potential role of miRNA in these responses. 
Microarray analysis was performed on 3 independent cultures per data point to 
determine the temporal nature of global miRNA expression profiles in the treated 
cells. Differentially expressed miRNA (DEM) were identified by performing a time 
course analysis, implemented in the AgiMicroRna package. This methodology 
allowed the identification of miRNAs which respond differently over time in each 
treatment group relative to the control. Treatment with the AR antagonist BIC did not 
significantly alter the expression of miRNA at any timepoint compared with the time-
matched control. In contrast, treatment with the AR agonists MIB and DHT resulted 
in significant changes in the expression of miRNA (Tables 1-2). All the miRNA 
affected by DHT were found to respond at 24 hours of treatment, with their 
deregulation being consistent at 120 hours. For MIB, miRNA were only determined to 
be affected by the treatment at 120 hours. Some of the identified DEM were affected 
by both AR agonists (miR-221, miR-99a, miR-1246, and miR-1290), while others 
were affected uniquely by one of the tested compounds (e.g. miR-210 for MIB and 
miR-494 for DHT). 
 
To validate the reliability of the microarray data qRT-PCR was used to assess the 
expression levels of five miRNA in the same samples used for microarray analysis.  
This analysis found a high degree of concordance between the levels of miRNA 
determined by qRT-PCR and microarrays, verifying the reliability of the microarray 
data (Fig.2).  
 
Expression of miR-221 
 
A defining feature of MIB treatment of LNCaP cells was the significant decrease in 
the expression of miR-221, also seen in DHT-treated cells, but less pronounced 
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(Tables 1 and 2). Increased expression of miR-221 has been shown to be involved in 
prostate cancer development and the progression to AR agonist independence (Gilardi 
et al., 2007; Sun et al., 2009; Kneitz et al., 2014; Sun et al., 2014). Our findings 
showing a decrease in expression are consistent with the AR responsiveness of 
LNCaP cells. Thus understanding this responsiveness may offer insights into the role 
of miR-221 in the progression of AR agonist independence. To investigate this 
interaction further we examined how expression of miR-221 relates to exposure to a 
range of MIB doses (from 1pM to 10nM). As expected MIB treatment resulted in a 
concentration dependent induction of LNCaP proliferation and PSA secretion 
(Fig.3A). Conversely, MIB treatment resulted in a concentration-dependent decrease 
in the expression of miR-221, up to 4-fold (Fig.3B). In these conditions, both PSA 
and proliferation were significantly inversely correlated with miR-221 expression (r=-
0.8780 and -0.9053, respectively, p<0.05). 
 
Expression of miR-210  
Among the miRNA displaying significant expression changes in response to MIB 
treatments was miR-210, a miRNA known to be upregulated by hypoxia and involved 
in driving cellular adaptations to low oxygen levels (Camps et al., 2008; Chan et al., 
2009). Indeed, we verified that in the absence of MIB, miR-210 levels in LNCaP cells 
were increased following hypoxia (Fig.4A). As a positive control it was also 
demonstrated that this treatment also caused the induction of the prototypical hypoxia 
responsive gene, the vascular endothelial growth factor (VEGF) (Fig.4B). 
  
To examine further the link between AR activation and miR-210 induction we 
examined the effect of doses of MIB on expression of this miRNA (Fig.4C) using 
qRT-PCR. Induction of miR-210 was observed in response to high doses of MIB 
(1nM and 10nM), but not as a result to treatment with lower doses. MIB treatment 
also resulted in increased levels of VEGF (Fig.4D), with miR-210 and VEGF 
displaying significantly correlated increases following MIB treatment (Pearson 
correlation 0.86, P<0.05, Fig.4E). 
 
Mabjeesh et al., 2003 reported that treatment of LNCaP cells with AR agonists was 
able to induce the HIF1α protein in conditions of normoxia via an autocrine loop 
involving increased epidermal growth factor (EGF) production and secretion. This 
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was therefore considered a potential mechanism by which MIB could induce miR-210 
and VEGF in conditions of normoxia. However, no EGF was detected in the cell 
media in LNCaP cells treated with vehicle or various MIB doses (Suppl.Fig.3).  
 
Discussion 
 
In this study we examined the effect of treatment with AR agonists and an AR 
antagonist on miRNA expression in the androgen-dependent LNCaP prostate cancer 
cell line. To the best of our knowledge this is the first study to directly investigate the 
temporal effects of AR agonists and antagonists on global miRNA profiles in prostate 
cancer cells. One obvious limitation of this approach is that it does not take into 
account the role of non-parenchymal cells in modulating the prostate response to AR 
signalling. Nevertheless, although in vitro studies can only replicate limited aspects of 
the in vivo response to androgens, valuable insights can still be obtained in regards to 
the involvement of miRNA to AR signalling and thus potentially to prostate cancer 
development. Another limitation of this study is that for microarray miRNA profiling 
a single concentration of each compound was studied, at different phases of the 
proliferation curve, and therefore in future studies it would be of use to study these 
compounds at concentrations of similar potency. 
An intuitive effect of AR antagonists on miRNA expression in prostate cancer cells 
would be the reversal of the effects of AR agonists. However, it is also possible that 
AR antagonists have additional effects on miRNA due to the recruitment of 
alternative co-regulators, activators and repressors, to the AR or by acting through AR 
independent pathways. An interesting hypothesis is that miRNA specifically affected 
by AR antagonists can have important phenotypic consequences, such as being 
involved in the progression of prostate cancer cells to a state of AR independence. To 
identify potential subsets of miRNA specifically affected by AR antagonists we 
examined LNCaP cells, cultured in the absence of AR agonists, treated with BIC. The 
BIC treatment used here was demonstrated to be able to inhibit AR-agonist induced 
proliferation of LNCaP cells (Suppl.Fig.1-2). Nevertheless, in this study no miRNA 
were identified as being significantly differentially expressed due to BIC treatment 
alone. These findings are consistent with the phenotypic effects of BIC being the 
antagonist of AR agonists, with few, if any, distinct effects on miRNA. However, 
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further investigations with more compounds and in different cell lines are required to 
rule out the possibility that AR antagonists have effects on prostate miRNA 
expression that go beyond the reversal of AR agonism. 
 
In contrast to BIC, the AR agonists DHT and MIB had clear effects on the expression 
of miRNA in the LNCaP cells (Tables 1-2). Some of the identified miRNA were 
differentially expressed in response to treatment with both DHT and MIB, while 
others were responsive to only one of the tested compounds.  It is quite likely that the 
majority of miRNA affected by both AR agonists are under direct regulation by the 
AR or are associated with the phenotypic changes induced by the compounds. One of 
the commonly affected miRNA identified here was miR-99a. This miRNA has been 
demonstrated previously to be under direct transcriptional regulation of the AR and to 
be involved in the direct post-transcriptional regulation of a number of AR responsive 
genes (Sun et al., 2014). This miRNA is also a suppressor of proliferation and PSA in 
prostate cells (Sun et al., 2011). The repression of this miRNA observed following 
treatment with both MIB and DHT could contribute to the observed increase in 
proliferation and PSA secretion of LNCaP cells (Fig.1). 
 
An interesting finding was that both DHT and MIB treatment caused a significant 
downregulation of miR-221, a miRNA strongly implicated in prostate cancer (Tables 
1-2; Fig.3).  Higher expression of miR-221 has been linked to the progression of 
prostate cancer cells from androgen-dependency to androgen-independent growth 
(Sun et al., 2009; Sun et al., 2014), with greater proliferation and aggressiveness of 
prostate cancer cell lines (Galardi et al., 2007), and with worse prognosis in high-risk 
prostate cancer patients (Kneitz et al., 2014). However, previous studies had not 
determined how expression of this miRNA is affected by exposure to AR agonists. 
Unexpectedly, in this study we have found that treatment with AR agonists caused the 
reduced expression of oncogenic miR-221 in the LNCaP cell line. Interestingly, the 
sensitivity of miR-221 to MIB doses appears to be the reverse of the effects of the 
chemical on cell numbers and PSA secretion (Fig.3). This observation indicates a 
more complex role for miR-221 in prostate cancer development than previously 
recognised. One possible interpretation of this observation is that AR signalling 
mediated the repression of miR-221 as a mechanism of maintaining proliferative 
prostate cells in a state of androgen-dependency. In this case these cells will then 
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return to a quiescent state more rapidly when the AR signalling is terminated. Further 
experimental work is required to determine the relevance and importance of the AR-
miR-221 interaction in vivo. 
 
Another interesting miRNA that was affected by both DHT and MIB was miR-1290. 
This miRNA has previously been reported to be a circulating prognostic marker for 
castration-resistant prostate cancer (Huang et al., 2014). This miRNA has been linked 
to inhibition of the cell cycle and promotion of apoptosis in neuronal and lung 
carcinoma cells by targeting p27 and BCL2 (Yelamanchili et al., 2014; Kim et 
al.2014). Interestingly, this is an evolutionary young, great-ape specific miRNA 
(Yelamanchili et al., 2014). Such species-specific miRNA repertoire may be 
important determinants of differential species responses to equivalent xenobiotic 
exposures such as AR agonists (Koufaris & Gooderham, 2013).  
 
We also determined in this study miRNA responses that were specific to only one of 
the tested compounds. Such compound-specific effects on miRNA could be due to a 
variety of technical reasons e.g. different potency of AR activation. It is also known 
that AR agonists can also have distinct biological effects. For example, in addition to 
effects on AR, MIB can also activate the progesterone receptor besides the AR, which 
is not the case for DHT (Cops et al., 2008). The differential effects of AR agonists on 
miRNA could potentially be important in determining differential effects of 
compounds on prostate cells or assist in identifying mode of action of such chemicals.  
 
An interesting example of a compound specific miRNA response identified here was 
the induction of miR-210 following MIB treatment (Fig.4). This miRNA is activated 
by hypoxia and is involved in driving cell adaptations to lack of oxygen (Giannakakis 
et al., 2008; Chan et al., 2009). In a previous study it has been reported that 
expression of miR-210 is induced in prostate cancer cell lines exposed to hypoxia 
(Quero et al., 2010). However, here it was demonstrated that MIB could induce this 
miRNA in cell culture conditions with adequate oxygen concentrations, suggesting 
functions for this miRNA beyond its established role in hypoxia. The effect on miR-
210 was only observed at high doses of MIB (Fig.4). Consequently the lack of 
response to DHT in this case may reflect the lower potency of the compound to 
activate the AR. We did not clarify here the mechanism by which AR agonists can 
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activate miR-210 in conditions of normoxia, but activation of miR-210 in vivo could 
be important in driving the metabolic changes observed in prostate cancer (Vaughan 
et al., 2013).  
 
Prostate cancer is currently the most commonly diagnosed cancer in males and a 
prevalent cause of global mortality. Consequently there is considerable interest in 
delineating the molecular mechanisms implicated in the initiation and progression of 
the disease. Research into the contribution of miRNA to prostate cancer development 
holds considerable promise. Firstly, miRNA that are key mediators of AR signalling 
could be novel therapeutic targets (Deng et al., 2013). Secondly, circulating miRNA 
could prove to be easily accessible biomarkers for the disease, either in plasma (Lin et 
al., 2014) or in prostate fluid (Selth et al., 2014).  This study demonstrates that direct 
profiling of the effects of AR agonists and antagonists on miRNA expression is a 
methodological approach that can assist towards clarifying the role of these genes in 
AR signalling and prostate cancer. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
References 
 
AbD Serotec (2009). BUF012A/B alamarBlue® Product Datasheet. Available from 
http://static.abdserotec.com/uploads/BUF012-technical-datasheet-2011.pdf [Accessed 
01.07.2012] 
Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle 
JM, Ragoussis J. hsa-miR-210 is induced by hypoxia and is an independent 
prognostic factor in breast cancer. Clin Cancer Res. 2008 1;14(5):1340-8. 
Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-
210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur 
cluster assembly proteins ISCU1/2. Cell Metab. 2009 10(4):273-84.  
Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, Tilley WD. 
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells 
are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol 
Biol. 2008 ;110(3-5):236-43.  
Deng JH, Deng Q, Kuo CH, Delaney SW, Ying SY. MiRNA targets of prostate 
cancer. Methods Mol Biol. 2013;936:357-69.  
Fradet Y. Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev 
Anticancer Ther. 2004 Feb;4(1):37-48.  
Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG. 
miR-221 and miR-222 expression affects the proliferation potential of 
human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007 
10;282(32):23716-24.  
Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li 
C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L. miR-
210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian 
cancer. Cancer Biol Ther. 2008 7(2): 255-264. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr 
Rev. 2002 23(2):175-200. 
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004 
25(2):276-308. 
Hodgson MC, Astapova I, Hollenberg AN, Balk SP (2007). Activity of androgen 
receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and 
SMRT corepressors. Cancer Res 67(17): 8388-8395. 
Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, 
Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, 
Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as 
Prognostic Markers in Castration-resistant Prostate Cancer. Eur Urol. 2014 13. pii: 
S0302-2838(14)00687-3.  
Johnson WE, Li C, Rabinovic A (2007). Adjusting batch effects in microarray 
expression data using empirical Bayes methods. Biostatistics 8(1): 118-127. 
Kim KB, Kim K, Bae S, Choi Y, Cha HJ, Kim SY, Lee JH, Jeon SH, Jung HJ, Ahn 
KJ, An IS, An S. MicroRNA-1290 promotes asiatic acid-induced apoptosis by 
decreasing BCL2 protein level in A549 non-small cell lung carcinoma cells. Oncol 
Rep. 2014 32(3):1029-36.  
Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, 
Kneitz S, Scholz CJ, Ströbel P, Gessler M, Riedmiller H, Spahn M. Survival in 
patients with high-risk prostate cancer is predicted by miR-221, which regulates 
proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and 
SOCS3. Cancer Res. 2014 1;74(9):2591-603. 
Koufaris C, Wright J, Currie RA, Gooderham NJ. Hepatic microRNA profiles offer 
predictive and mechanistic insights after exposure to genotoxic and epigenetic 
hepatocarcinogens. Toxicol Sci. 2012 128(2):532-43.  
Koufaris C, Gooderham NJ. Are differences in microRNA regulation implicated in 
species-dependent response to toxicological exposures? Toxicol Sci. 2013 
131(2):337-42. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 17 
Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, 
Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin 
MA. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and 
contributes to prostate cancer progression. Cancer Res. 2013 1;73(3):1232-44. 
Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler 
MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, 
Horvath LG. Circulating microRNAs are associated with docetaxel chemotherapy 
outcome in castration-resistant prostate cancer. Br J Cancer. 2014 13;110(10):2462-
71. 
Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human 
prostate. Best Prac Res Cl En. 2008 22(2): 207-221. 
Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens 
stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase 
receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin 
Cancer Res. 2003 9(7):2416-25. 
Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, 
Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M, Kallioniemi O. 
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer 
cells. Cancer Res. 2011 1;71(5):1956-67.  
Ottman R, Nguyen C, Lorch R, Chakrabarti R. MicroRNA expressions associated 
with progression of prostate cancer cells to antiandrogen therapy resistance. 
Mol Cancer. 2014 3;13:1. 
Papaioannou MD, Koufaris C, Gooderham NJ. The cooked meat-derived mammary 
carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) elicits 
estrogenic-like microRNA responses in breast cancer cells. Toxicol Lett. 2014 
17;229(1):9-16.  
Quero L, Dubois L, Lieuwes NG, Hennequin C, Lambin P. miR-210 as a marker of 
chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol. 
2011 Oct;101(1):203-8.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, 
Tanaka Y, Dahiya R. Regulatory role of mir-203 in prostate Cancer progression 
and metastasis. Clin Can. Res. 2011 15;17(16):5287-98.  
Sedelaar JP, Isaacs JTC. Tissue culture media supplemented with 10% fetal calf 
serum contains a castrate level of testosterone. Prostate 2009 69(16): 1724-1729. 
Selth LA, Roberts MJ, Chow CW, Marshall VR, Doi SA, Vincent AD, Butler LM, 
Lavin MF, Tilley WD, Gardiner RA. Human seminal fluid as a source of prostate 
cancer-specific microRNA biomarkers. Endocr Relat Cancer 2014 21(4):L17-21.  
Sokolowski JH, Geng S. Biological evaluation of mibolerone in the female Beagle. 
Am J Vet Res. 1977 38(9): 1371-1376. 
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 
and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 
2009 15;69(8):3356-63.  
Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk 
CA, Dutta A. miR-99 family of MicroRNAs suppresses the expression of prostate-
specific antigen and prostate cancer cell proliferation. Cancer 
Res. 2011 15;71(4):1313-24.  
Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff 
PW. MiR-221 promotes the development of androgen independence 
in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2014 
May 22;33(21):2790-800.  
Szczyrba J, Löprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland 
W, Stöhr R, Hartmann A, Wullich B, Grässer F. The microRNA profile of prostate 
carcinoma obtained by deep sequencing. Mol Cancer Res. 2010 Apr;8(4):529-38. 
Vaughan RA, Garcia-Smith R, Trujillo KA, Bisoffi M. Tumor necrosis factor alpha 
increases aerobic glycolysis and reduces oxidative metabolism inprostate epithelial 
cells. Prostate 2013;73(14):1538-46.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
Yelamanchili SV, Morsey B, Harrison EB, Rennard DA, Emanuel K, Thapa I, Bastola 
DR, Fox HS. The evolutionary young miR-1290 favors mitotic exit and 
differentiation of human neural progenitors through altering the cell cycle proteins. 
Cell Death Dis. 2014 Jan 9;5:e982. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
Figures & Tables 
 
Fig.1 Effects of BIC, DHT, and MIB treatments on proliferation and PSA 
secretion in LNCaP cells over time (A) Effect of vehicle control and DHT, MIB, and 
BIC on LNCaP cell numbers with time; (B); Effect of vehicle control and DHT, MIB, 
and BIC on LNCaP PSA secretion with time. Presented as the mean of three or four 
independent cultures  with S.D. error bars. Statistical analysis was performed by 1-
way ANOVA with Dunnett‟s post hoc test comparing to the vehicle control time 
point, where *** indicates P<0.001, **P<0.01 and *P<0.05.   
 
Fig.2 qRT-PCR verification of microarray results for AR agonist treated cells. 
On the Y-axis the mean hybridization values for the selected miRNA as measured 
using microarrays are plotted. On the X-axis the mean values for the same miRNA as 
determined by qRT-PCR are plotted. Pearson‟s correlation is indicated. Each 
individual point is the mean value from mibolerone-treated cells at 120 hours (except 
for miR-494 which is the mean value from DHT-treated cells at 24 hours). qRT-PCR 
data normalised to RNU6B. Presented as mean of 3 independent  cultures. 
 
Fig.3 Effect of MIB on miR-221 expression (A) Effect of MIB  on cell numbers and 
PSA secretion of LNCaP cells ; Presented as mean of at least six independent cultures 
with S.D. error bars. Statistical analysis performed by 1-way ANOVA with Dunnett‟s 
post hoc test, comparing against the vehicle control where *** indicates P<0.001, 
**P<0.01 and *P<0.05.  (B) Measurement of mature miR-221 levels in same samples 
by qRT-PCR. Data are mean of 3 independent cultures with S.D error bars.  Cells 
treated for 120 hours. 
 
Fig.4 MIB specific induction of the hypoxia-associated miR-210 (120 hours 
treatment). (A) Comparison of mature miR-210 levels in LNCaP cells in normoxia 
and hypoxia (3 independent cultures); (B) Comparison of VEGF mRNA levels in 
LNCaP cells in normoxia and hypoxia (3 independent cultures); (C) Measurement of 
mature miR-210 levels by qRT-PCR in LNCaP cells treated with range of MIB doses; 
(3 independent cultures (except VC, N=2) (D) Measurement of VEGF mRNA levels 
by qRT-PCR in LNCaP cells treated with range of MIB doses (3 independent cultures 
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(except VC, N=2); (E) Pearson correlation between mean miR-210 and VEGF levels 
in same LNCaP samples treated with range of MIB concentrations. All graphs, errors 
bars indicate S.D 
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Tables 
 
Table 1 MIB treatment induced changes in miRNA expression 
 
miRNA Fold change 
cchange 
FDR pval 
miR-221 2.5 DOWN 0.01592 
miR-196b 1.5 DOWN 0.15671 
miR-1246 1.9 DOWN 0.25493 
miR-1290 1.8 DOWN 0.25493 
miR-210 1.7 UP 0.25493 
miR-182 1.3 DOWN 0.25493 
miR-30a 1.8 DOWN 0.28308 
miR-99a* 1.2 DOWN 0.28308 
miR-720 1.6 UP 0.28308 
miR-105 1.1 DOWN 0.28308 
miR-99a 1.5 DOWN 0.28308 
miR-7 1.8 UP  0.28308 
Tabulated miRNA are those found to have a significant temporal change in expression 
levels following treatment with MIB with a false discovery rate (FDR) less than 0.3 
between the examined timepoints (8, 24, and 120 hours of treatment). Values shown 
are mean fold changes compared to time-matched vehicle control (3 independent  
cultures  per condition ). 
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Table 2 DHT treatment induced changes in miRNA expression 
 
miRNA Fold change FDR pval 
let-7e 2.1 DOWN  0.27568 
miR-16 2.4 DOWN  0.27568 
let-7c 1.5 DOWN  0.27568 
let-7b 1.3 DOWN 
DODOWN 
0.27568 
miR-494 2.5 UP 0.27568 
miR-200b 2.3 UP  0.27568 
miR-98 2.0 UP  0.27568 
miR-1290 1.7 UP  0.27568 
miR-183 2.0 DOWN  0.27568 
miR-151-5p 1.9 DOWN  0.27568 
miR-23a 2.0 DOWN 
DDODODOWN 
0.27568 
miR-107 2.2 DOWN  0.27568 
miR-23b 2.0 DOWN  0.27568 
miR-26b 2.3 DOWN  0.27568 
miR-195 2.0 DOWN  0.27568 
miR-30c 1.5 DOWN  0.27568 
miR-1260 1.7 DOWN 0.27568 
miR-100 1.5 DOWN   0.27568 
let-7a 1.7 DOWN  0.27568 
let-7d 1.5 DOWN 0.27568 
miR-1280 2.3 UP 0.27568 
miR-99a 1.5 DOWN   0.27568 
miR-30b 2.1 DOWN  0.27568 
miR-1246 1.6 DOWN  0.27568 
miR-125b-2* 1.5 DOWN  0.27568 
miR-15b 2.1 DOWN  0.27568 
let-7i 1.6 DOWN  0.27568 
miR-425 1.7 DOWN  0.27568 
miR-24 1.9 DOWN  0.27568 
miR-203 1.6 DOWN  0.27568 
miR-638 1.4 UP 0.27568 
miR-17 2.0 DOWN 
DOWN 
0.27568 
miR-25 1.5 DOWN 
DOWN 
0.27568 
miR-148a 2.1 DOWN  0.28423 
miR-374b 1.4 DOWN  0.28423 
miR-103 2.1 DOWN  0.28423 
miR-15a 2.0 DOWN  0.28423 
miR-93 1.7 DOWN  0.28423 
miR-221 1.5 DOWN  0.28423 
miR-200c 1.8 DOWN  0.28423 
 Tabulated miRNA are those found to have a significant temporal change in expression 
levels following treatment with MIB with a false discovery rate (FDR) less than 0.3 
between the examined timepoints (8, 24, and 120 hours of treatment). Values shown 
are mean fold changes compared to time-matched vehicle control. (3 independent 
cultures  per condition ). 
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Supplementary Figure Legends 
 
Suppl.Fig.1: Effects of treatments with DHT, MIB, and BIC on LNCaP 
proliferation.  
In panels (A)-(C) the effects of the three tested compounds on LNCaP proliferation as 
measured by alamarBlue® is shown. In panel (D) the ability of a range of BIC doses 
to inhibit proliferation induced by 2nM DHT is presented. Shaded area represents 
95% confidence interval for determination of Log EC50 (dotted line). Values are 
mean ± S.E.M error bars from 4 independent  cultures; Vc is vehicle control; -ve is 
negative control (media); +ve is 2 nM DHT alone. 
 
Suppl.Fig.2: Effects of treatments with DHT, MIB, and BIC on PSA secretion by 
LNCaP.  
In panels (A)-(C) the effects of the three tested compounds on PSA secretion are 
shown (D) the ability of a range of BIC doses to inhibit PSA secretion induced by 
2nM DHT is presented. Values are single determinations, 
 
Suppl.Fig.3: EGF secretion in MIB treated LNCaP  
(A) Standard curve of EGF.  Data are mean of two replicates per standard; (B) EGF 
protein expression from MIB-treated LNCaP.  Data are mean of seven replicates for 
samples with S.D. error bars and two replicates for EGF blank (0 pg/mL EGF). 
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